- Nu.Q® Technology
Our technology detects characteristic epigenetic changes in nucleosomes that occur from the earliest stages of cancer, sepsis and other diseases.
-
- Our Tests
- Human Health
- Nu.Q® NETs
Nu.Q® NETs is a groundbreaking CE-marked diagnostic solution that clinicians can use to detect NETosis.
- Nu.Q® Discover
Buy our Nu.Q® Discover H3.1 Research Use Only Assay
- Animal Health
- Nu.Q® Vet Cancer Test
Nu.Q® Vet Cancer Test is an affordable, accessible blood test that detects cancer in dogs.

High-throughput epigenetic profiling immunoassays for accelerated disease research and clinical development
- Share
- Tweet
- Share on Facebook
- Share


Paper titled: High-throughput epigenetic profiling immunoassays for accelerated disease research and clinical development
Priscilla Van den Ackerveken, Clotilde Hannart, Dorian Pamart, Robin Varsebroucq, Marion Wargnies, Olivia Thiry, Marie Lurkin, Séverine Vincent, Muriel Chapelier, Guillaume Rommelaere, and Marielle Herzog
Published in Journal of Biological Chemistry
Subscribe for Volition product updates.
Or, click here for Investor Updates and press releases.
"*" indicates required fields